RESUMEN
BACKGROUND: The aim of this paper was to understand the role of prophylaxis with levetiracetam at skin incision in preventing convulsive intraoperative seizures (IOS) during neurosurgical procedures with and without intraoperative neuromonitoring (IONM). METHODS: Authors retrospectively reviewed the Institutional database for cases of supratentorial brain tumors undergoing surgical resection performed from January 2021 to October 2022. Patients were operated on both under general anesthesia and awake, using motor-evoked potentials (MEP) and direct cortical stimulation for cortical mapping. 1000 mg ev of Levetiracetam before skin incision in case of a history of seizures was administrated. We excluded all infratentorial cases. RESULTS: Three hundred fisty three consecutive cases were retrieved. IOS occurred in 22 patients (6.2%). Prophylaxis with Levetiracetam was administered in 149 patients, and IOS occurred in 16 cases (10.7%) in this group of patients. The IOS rate in the case of no Levetiracetam prophylaxis administration (3.5%) was significantly lower (P<0.001, OR=3.38 [1.35-8.45], RR=3.12 [1.32-7.41]). The Penfield technique stimulation evoked seven of all 22 IOS reported (31.8%) (P=0.006, RR 5.4 [1.44 -20.58], OR 21 [2.3-183.9]), and the train-of-five technique stimulation caused two of all registered IOS (8.7%) (P=0.2, RR 2.3 [0.99-5.67], OR 6.5 [0.55-76.17]). Transcranial MEPs evoked no IOS. CONCLUSIONS: Under levetiracetam prophylaxis, the IOS rate was not significantly lower than in the group of patients without Levetiracetam prophylaxis, regardless of the histology of the tumor and IONM. Neither the transcranial stimulation (MEP) nor train-of-five technique stimulation increases the risk of convulsive IOS, as Penfield technique stimulation does.
RESUMEN
OBJECTIVE: Superficial Middle Cerebral Vein (SMCV) is an anastomotic vein frequently exposed during surgery. Changes in the pattern of cerebral venous outflow can occur in many pathological settings. We explored the hypothesis that the growth of an intracranial tumor could determine alterations in the venous outflow. We analyzed SMCV anatomical variants in patients undergoing surgery for intracranial tumors; we furthermore focused on association with histology. METHODS: We retrospectively collected data of 120 patients undergoing surgery, 60 presenting intracranial tumor and 60 presenting cerebral aneurysms (control group). Tumor series was divided into "Low Growth-Rate tumors" (WHO grade I and II) and "High Growth-Rate tumors" (WHO grade III and IV). Anatomical variants of SMCV were analyzed on intraoperative videos and then classified as Type 1 (normotrophic), 2 A (hypotrophic) and Type 2B (absent/atrophic). We furthermore defined as Type 2 any alteration of the SMCV (2 A+2B) encountered. Relationships among SMCV types and both populations were analyzed using the chi-squared test; values of p < 0.05 were considered statistically significant. RESULTS: We found a positive correlation between the presence of a primary brain tumor and Type 2B SMCV (PC.004, p < 0.05) and Type 2 SMCV (PC.000, p < 0.05). Specifically, we found a strong correlation between the absence of SMCV (Type 2B) and both tumors subgroups. Thus, the growth of a primary brain tumor seems to affect the cerebral local outflow. CONCLUSIONS: Primary brain tumors seem to alter local venous network of SMCV. Clinical and oncological implications remain subject of further investigation.